Likewise, within the CD8+ T cell population, the percentage of granzyme B+ effector CD8+ T cells (Figure 8F) was significantly higher in tumors of mice receiving anti‐MMR Nb‐IMDQ in comparison to the control group, suggesting an enhanced anti‐tumor immunity. Here, CD8A is linked to neoplasm.